Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PER2 | O15055 | 1/20 | 0.41 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28528640 | 1.00 | BRD4 (0.44) | BRD4LMNAPER2CRY2APEX1 | |
| SCHEMBL21389171 | 1.00 | BRD4 (0.44) | BRD4LMNAPER2CRY2APEX1 | |
| SCHEMBL9301677 | 0.86 | GSK3A (0.41) | PER2CRY2APEX1BLMKMT2A | |
| SCHEMBL21384045 | 0.85 | PER2 (0.41) | BRD4LMNAPER2CRY2APEX1 | |
| SCHEMBL28429109 | 0.85 | PER2 (0.41) | BRD4LMNAPER2CRY2APEX1 | |
| SCHEMBL11620380 | 0.83 | APEX1 (0.60) | BRD4LMNAPER2CRY2APEX1 | |
| SCHEMBL21389114 | 0.81 | BRD4 (0.45) | BRD4LMNAPER2CRY2APEX1 | |
| SCHEMBL21389109 | 0.81 | APEX1 (0.62) | BRD4LMNAAPEX1BLMKMT2A | |
| SCHEMBL24880111 | 0.81 | BRD4 (0.45) | BRD4LMNAPER2CRY2APEX1 | |
| SCHEMBL21389170 | 0.81 | APEX1 (0.62) | BRD4LMNAAPEX1BLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11535660-B1 | Modulators of G-protein coupled receptors | Cannot Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| US-11535660-B1 | Modulators of G-protein coupled receptors | Cannot Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| CN-112236161-A | Modulators of G protein-coupled receptors | 卡莫特治疗学股份有限公司 | 2021-01-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | BRD4 1415/4885LMNA 3629/4885PER2 1938/4885 |
| US-11535660-B1 | Modulators of G-protein coupled receptors | GIPR, GLP1R, GCGR | BRD4 1441/4885LMNA 3907/4885PER2 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.